Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total
June 09, 2026
June 09, 2026
BOSTON, Massachusetts, June 9 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:
* * *
Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total
*
The Life Sciences team advised Nurix Therapeutics, Inc. on a global collaboration with Roche to develop and commer . . .
* * *
Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total
*
The Life Sciences team advised Nurix Therapeutics, Inc. on a global collaboration with Roche to develop and commer . . .